within Pharmacolibrary.Drugs.ATC.J;

model J04BA02
  extends Pharmacokinetic.Models.PK_2C_enteral(
    weight         = 70,
    F              = 0.9,
    Cl             = 6.666666666666667e-07,
    adminDuration  = 600,
    adminMass      = 100 / 1000000,   // mg → kg
    adminCount     = 1,
    Vd             = 0.0015,
    Cmin           = 0.001,
    Cmax           = 0.01,
    Ctox_peak      = 0.02,
    Ctox_trough    = 0.01,
    ka             = 0.0038333333333333336,
    Tlag           = 0,            
    Vdp             = 0.0012,
    k12             = 0.06,
    k21             = 0.06
    
  );

  annotation (Documentation(
    info       = "<html><body><table><tr><td>Drug:</td><td>J04BA02</td></tr><td>route:</td><td>oral</td></tr><tr><td>n-compartments</td><td>2</td></tr></table><p>Dapsone is a synthetic sulfone antibiotic used primarily in the treatment of leprosy (Hansen's disease), dermatitis herpetiformis, and as prophylaxis against Pneumocystis jirovecii pneumonia. It has bacteriostatic activity against Mycobacterium leprae and is sometimes used off-label for other dermatological conditions. Dapsone is still approved and in use today, especially where leprosy remains endemic.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic parameters in healthy adult volunteers, oral administration.</p><h4>References</h4><ol><li><p>Zuidema, J, et al., &amp; Merkus, FW (1986). Clinical pharmacokinetics of dapsone. <i>Clinical pharmacokinetics</i> 11(4) 299–315. DOI:<a href=\"https://doi.org/10.2165/00003088-198611040-00003\">10.2165/00003088-198611040-00003</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3530584/\">https://pubmed.ncbi.nlm.nih.gov/3530584</a></p></li><li><p>Pieters, FA, &amp; Zuidema, J (1986). The pharmacokinetics of dapsone after oral administration to healthy volunteers. <i>British journal of clinical pharmacology</i> 22(4) 491–494. DOI:<a href=\"https://doi.org/10.1111/j.1365-2125.1986.tb02924.x\">10.1111/j.1365-2125.1986.tb02924.x</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/3768260/\">https://pubmed.ncbi.nlm.nih.gov/3768260</a></p></li><li><p>Thiboutot, DM, et al., &amp; Garrett, S (2007). Pharmacokinetics of dapsone gel, 5% for the treatment of acne vulgaris. <i>Clinical pharmacokinetics</i> 46(8) 697–712. DOI:<a href=\"https://doi.org/10.2165/00003088-200746080-00006\">10.2165/00003088-200746080-00006</a>  PUBMED:<a href=\"https://pubmed.ncbi.nlm.nih.gov/17655376/\">https://pubmed.ncbi.nlm.nih.gov/17655376</a></p></li></ol></body></html>",
    revisions  = "<html><body><ul><li>06/2025 initial model generated by LLM gpt-4.1 from general data</li></ul></body></html>"
  ));
end J04BA02;
